Adoption, implementation, and evaluation of the HEARTS initiative on blood pressure outcomes: a quality improvement project in a large healthcare system in the United States Authors: Mark Shaffer, Emily Ridley, Kerri Williams, Rebecca S Smith, James B Gettys, Gregg M Talente, Katherine Gettys, Donald J DiPette, Carolin C Hoeflich Published: 2026 ABSTRACT SummaryBackgroundThe HEARTS Initiative, based on the World Health Organization Global HEARTS Initiative and the Pan American Health Organization HEARTS in the Americas program, has been used globally to improve cardiovascular health. Given a literature dearth on its implementation in the United States, this study evaluated the impact of a HEARTS-derived quality improvement program on achieving at-target, follow-up blood pressure (BP) among patients with elevated BP (EBP).MethodsElectronic health record data from 191,418 adult patients with EBP (i.e. ≥140 mmHg systolic and/or ≥90 mmHg diastolic) visiting an eligible primary care center between 2021 and 2024 was utilized. HEARTS-based initiatives were gradually introduced systemwide. Patients whose first EBP encounter during the study period occurred in 2021 and 2024 comprised the pre-intervention and post-intervention cohorts, respectively. At-target follow-up BP was defined as a follow-up BP reading of <140 mmHg systolic and <90 mmHg diastolic taken within 6 months of index EBP. Descriptive statistics, bivariate analyses, and generalized linear mixed-effects models were conducted.FindingsThis system's HEARTS Maturity Index score improved from 2 to 11. Patients were predominately female (108,407; 56.6%), 65+ years old (74,054; 38.7%), and White (130,507; 69.1%). After adjusting for site-level clustering and key predictors, the post-intervention cohort had higher odds of achieving at-target BP within 6 months of index EBP, compared to the pre-intervention cohort (adjusted odds ratio = 1.14; 95% confidence interval = 1.11–1.18).InterpretationSuccessful integration of HEARTS serves as a salient opportunity for further research and efforts to tailor and disseminate these initiatives in the United States.FundingNone.Keywords: Hypertension, HEARTS, Primary care Research in context Evidence before this study The HEARTS Initiative, consisting of the World Health Organization (WHO) Global HEARTS Initiative and the Pan American Health Organization (PAHO) HEARTS in the Americas Program, is a structured approach to improve cardiovascular health in primary care settings, predominately through the prevention and management of hypertension. HEARTS-derived programs are being implemented in over 30 countries. However, the feasibility, acceptability, and impact of integrating a HEARTS-based program in the United States has been uncertain. The authors conducted a systematic search of PubMed and Google Scholar from January 2016 to March 2026 using the search terms “HEARTS”, “hypertension”, and “HEARTS in the Americas”. Prior studies have focused on the implementation of HEARTS in the Caribbean or Central or South American countries, such as Venezuela, Cuba, or Mexico. Further, a majority of previously published literature evaluated the impact of HEARTS-based initiatives among patients with hypertension, rather than among those with elevated blood pressure despite the clinical salience of assessing the impact of HEARTS-based interventions on mitigating hypertension development. No studies were found to have examined the impact of HEARTS in a large, healthcare system in the United States. Added value of this study To our knowledge, this is the first quality improvement study to evaluate the impact of a series of HEARTS-derived initiatives on achieving target blood pressure within 6 months of index elevated blood pressure reading in 191,418 adult patients with elevated blood pressure across 66 primary care offices in a single, large healthcare system in southeastern United States. A comprehensive roadmap to implementing interventions, including development of a standardized hypertension protocol, electronic health record system enhancements, and new monitoring tools, were elucidated to increase standardization of evidence-based care as well as improve detection and improved management of hypertension within this system. Our findings revealed favorable outcomes for achieving normotensive blood pressure with 6 months of index elevated reading. Subgroup analyses revealed opportunities for further exploration and tailoring of HEARTS-based initiatives to support select high-risk patient populations. Implications of all the available evidence Our findings provided evidence that HEARTS based initiatives can be successfully implemented within large healthcare systems in the United States. Optimization and specialization of these interventions for diverse clinical settings and patient populations could strengthen primary care efforts in achieving hypertension control in North America. Introduction Hypertension, a highly modifiable risk factor for cardiovascular disease and exacerbator for other diseases' progression, contributes to profound healthcare burden and expenditures in the United States (US).1, 2, 3, 4 National Health and Nutrition Examination Survey (NHANES) data from 2017 to 2020 estimated that 119.9 million adults in the US are living with hypertension, and only 22.5% of these adults have their hypertension controlled.5 In 2019, hypertension was associated with $2759 total, all-cause healthcare expenditure per person, according to Medical Expenditure Panel Survey data.2 The Center for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (WONDER) database revealed rising rates of hypertension-related mortality in the US.6 In 2010, the hypertension-related mortality rate was 5.1 per 100,000 individuals, compared to 6.4 per 100,000 individuals in 2020.6 However, temporal variability in blood pressure (BP) control rates is present.7 The age-adjusted proportion of US adults with hypertension who had controlled BP decreased from 54.1% in 2013–2014 to 48.3% in 2017–2020, but increased to 51.1% in 2021–2023.7 The implementation and evaluation of initiatives to improve BP control rates and mitigate suboptimal clinical outcomes associated with hypertension is necessary. HEARTS in the Americas, the World Health Organization's (WHO) Global Hearts, Million Hearts, the Kaiser Permanente Northern California model, and Target: BP™ are such initiatives.8, 9, 10, 11, 12, 13 The WHO HEARTS technical package was developed based on the success of the HEARTS in the Americas program and focuses on continuously improving primary healthcare to advance cardiovascular health equity.14,15 HEARTS stands for the six intervention pillars: Healthy lifestyle, Evidence-based treatment protocol, Access to medicines and technologies, Risk-based approach, Team-based care, System for monitoring.16 This initiative aims to strengthen healthcare systems by promoting gradual and sustainable integration of its interventions and standard clinical protocols, such as its Hypertension Clinical Pathway, into routine practice.14,17 Despite the salience of initiatives incorporating HEARTS elements, insufficient research has been conducted to evaluate HEARTS-based programs in US healthcare systems. This retrospective quality improvement study assessed a HEARTS-derived program on achieving at-target follow-up BP among adult patients with elevated blood pressure (EBP) in a large health care system located in the southeastern US. This program was a set of multifaceted BP initiatives that prioritized improving ambulatory BP measurement accuracy, standardizing hypertension treatment algorithms, and facilitating rapid review of hypertension outcome data. It was hypothesized that the series of HEARTS-based initiatives would be positively associated with reaching at-target follow-up BP within this population. Findings from this work could offer insights and potential avenues for the further assessment and development of HEARTS-derived programs implemented in US-based healthcare systems. Finally, the initial and current state of this healthcare system's primary care hypertension-related protocols were evaluated using the HEARTS Maturity Index framework.18,19 Methods Study design and population Electronic health records (EHR) from adult patients (i.e. 18+ years of age) with EBP (i.e. ≥140 mmHg systolic and/or ≥90 mmHg diastolic BP) at an encounter in one of 66 eligible departments (henceforth referred to as sites) providing primary care services during the study period (i.e. January 1, 2021–December 31, 2024) and implementing the HEARTS-based program were examined within this quality improvement study. Sites not focusing on primary care service provision or those without full integration of the HEARTS model were not included in this analysis as a location from which a patient could obtain an index EBP. All centers were under one large healthcare system, serving two regional markets (henceforth referred to as Market A and B) in South Carolina. Although Market A launched the electronic medical record system (EMR) in July 2015 for ambulatory and February 2016 for inpatient, Market B only implemented this EMR system in February 2021. The index EBP reading occurred at a primary care clinic, but the follow-up BP reading could have been taken at any location within this healthcare system within 6 months of the index EBP reading. Among 191,451 patients from one of the 66 sites, 33 patients were excluded due to having a follow-up systolic or diastolic BP value of 0 mmHg; these patients were assumed to have an inaccurate BP measurement. The final sample consisted of 191,418 EBP patients. The Institutional Review Board (IRB) of this healthcare system deemed the study as exempt. Overview and timeline of interventions The series of HEARTS-initiatives were developed and introduced within this healthcare system over a multiyear period with the predominate implementation occurring between 2022 and 2023. Pre-dating these interventions, there was localized work in standardizing hypertensive care through guidelines within Family Medicine and Internal Medicine residency programs.20 The first HEARTS-based department wide protocol, covering 10 offices, was developed in a Family Medicine department from 2021 to 2022.20 Recognizing salience of engaged leadership, the HEARTS-derived initiatives originated with support from key stakeholders across the health system. The Primary Care Clinical Specialty Council (henceforth referred to as the council), containing membership from Family Medicine, Internal Medicine, nursing, informatics, network quality, and pharmacy, was established in September 2022 and unified this healthcare system's four primary care departments. Hypertension was selected as the council's first clinical priority for system-wide standardization and quality improvement. Rather than a single moment of profound change, interventions were multiple, gradual, and complementary. Indeed, all initiatives were introduced progressively to ensure their acceptance by clinicians and administrative staff as well as feasibility and sustainability in diverse clinical workflows. The goal was to achieve full incorporation of the new workflow into all practices and ultimately to improve hypertension outcomes for our patients. Dissemination of the HEARTS-based protocols occurred in departmental and office-specific meetings while relevant materials were accessible via reference posters within clinical sites and on a primary care-specific intranet resource. A full list of interventions is listed in Table 1, administrative and infrastructure interventions are detailed in Supplemental Text 1, and EHR-based interventions are detailed in Supplemental Material 2. Here, several domains in which this healthcare system had the most success in following the HEARTS Initiative were elucidated. Table 1Review of HEARTS-based initiatives over time by scope and category of implementation.TimelineScopeInterventionCategoryPrior to 2021Academic PracticesSite specific hypertension guidelines for primary care developed by residency clinicsClinical GuidelineAugust 2021Health SystemPosters and mini cards attached to equipment on how to properly check BPInfrastructureSeptember 2021FM DepartmentFamily Medicine sites in Market B began installation of automated BP machines in each office with nursing trainingInfrastructureApril 2022FM DepartmentFamily Medicine sites in Market B established financial incentive for fiscal year 2022 for hypertension diver metrics for providersAdministrationJune 2022Health SystemEHR red letter alert changed from BP greater than 160/90 to 140/90EHRJuly 2022Health SystemSimple dotphrase created (.BP6) to display chart of last six recorded BP readingsEHRSeptember 2022Primary CareHypertension selected as priority by Primary Care Clinical Specialty CouncilAdministrationNovember 2022Health SystemRepeat BP alert launched in EHR prompting staff in all specialties to repeat BP if highEHRNovember 2022Specialty OfficesPatients without a primary care provider with high BP readings in specialty areas were automatically referred into primary careClinical Guideline, EHRNovember 2022Health SystemEstablished nurse triage protocols for elevated BP without cardiac or neurological symptoms to direct back to primary care rather than EDClinical GuidelineDecember 2022Health SystemBP displayed prominently in EHR (on Epic Storyboard) with abnormal values in redEHRDecember 2022Pilot PracticeRemote patient monitoring pilot program beginsAdministration, InfrastructureDecember 2022FM DepartmentFamily Medicine department-wide hypertension treatment protocol launchesClinical GuidelineJanuary 2023Health SystemHypertension SmartSet developed in EHREHRMay 2023Primary CareRemote patient monitoring program expands to Primary CareClinical Guideline, EHRMay 2023Health SystemAdvanced Rooming tip sheet created for nursing to clarify correct BP measurement, confirmation, and documentationClinical GuidelineSeptember 2023Health SystemUpdated ambulatory nurse standard workflow, requiring annual review of how to properly take BP readingsAdministrationClinical GuidelineSeptember 2023Primary CareHypertension Protocol Expands Across Primary Care, Based on FM ProtocolClinical GuidelineSeptember 2023Primary CareInsights Platform launched to view leadings metrics of hypertension by practice locationAdministration/InformaticsOctober 2023Health SystemHypertension Express Lane launched to streamline EHR workflow and guide treatment decisionsEHRApril 2025Primary CareStandardized nurse visit documentation for BP recheck visitsEHRAbbreviations: BP, Blood pressure; EHR, Electronic health record; FM, Family medicine. Review of HEARTS-based initiatives over time by scope and category of implementation. Abbreviations: BP, Blood pressure; EHR, Electronic health record; FM, Family medicine. Improved blood pressure measurement The foundation of hypertension care is accurate measurement. In the initial assessment, the council identified no standard training for correct use of automated BP cuffs nor an organizational standard for repeating elevated BPs. A formal training curriculum was developed with an easy-to-use reference sheet and a formal competency check-off to be completed by each clinical team member with a supervisor annually. This process included proper patient position and cuff selection, repeating elevated BPs, and correct documentation. Having reliable BP measurements was deemed essential by the council prior to implementing a more comprehensive treatment plan. Our physician and nursing leadership reviewed the literature and agreed that our standard for ambulatory BP measurement must be an automated cuff with the ability to measure and average BPs without a team member in the room, replicating the methodology used in the SPRINT trial.21 This change in BP measurement equipment was executed slowly site by site over several years. An inventory was developed, equipment ordered, and training performed. This took significant administrative support and financial investment. Equipment was tagged with visual aids from the American Heart Association and the American Medical Association's Target:BP program.12,22 Deployment of a standard treatment algorithm Improvements in BP measurement accuracy increased clinicians’ capacity to appropriately advance the treatment of hypertension. Standardized anti-hypertensive medication treatment algorithms and follow-up guidelines were launched in December 2022 for family medicine departments and in September 2023 for all primary care sites. Two important aspects of standardization included an algorithm with specific medications and doses as well as a clearly defined times for follow-up and medication intensification.20 In selecting medications, the council evaluated recently published evidence-based guidelines, including the clinical effectiveness of the antihypertensives, the potential for synergistic reduction in BP, the opportunity to mitigate side effects, and the safety and efficacy across diverse demographic groups. Further, dosing was simplified using once-daily formulations and fixed combination pills. Information was gathered and examined first by a small group within family medicine, internal medicine, and pharmacy departments across the system who had a keen interest in this project. After the initial algorithm was developed, additional colleagues such as OB/GYN, nursing, and administrative leads were asked to join the discussion and provide feedback. This algorithm was shaped from this collaborative work and the progressive buy-in of clinical leaders. Using the Kaiser Permanente algorithm as a starting point,23 the council substituted an ACE inhibitor (ACEi), with an angiotensin receptor blocker (ARB) to reduce the risk of cough and angioedema. The council selected an ARB in combination with a long-acting dihydropyridine calcium channel blocker (CCB) for the first step in the algorithm as evidence suggested that this combination has greater reduction in cardiovascular (CV) events than an ARB/ACEi + Thiazide.24 This combination also showed superior BP control in patients who were African American than an ARB/ACEi + Thiazide.25 By starting at half-maximal dose of both agents in a single–pill combination, the council achieved at-target BPs rapidly while minimizing side effects.26 After up-titrating the dose of the combination agent, if needed, a thiazide or thiazide-like diuretic was added. Prior data demonstrated the strong efficacy of these three classes as the initial choices for hypertension management.27 Selection of spironolactone as a fourth agent was based on a randomized crossover trial showing its superiority to other classes.28 The algorithm also contained a separate track for patients of child-bearing potential as the teratogenicity of ARBs and spironolactone excluded their use in this patient population. OB/GYN colleagues supported the use of a CCB with a thiazide (or thiazide-like) diuretic as the starting medications with a nonselective beta blocker/alpha-1 blocker as the third agent. Recommending a specific time interval for reassessment within the algorithm was critical in addressing therapeutic inertia and patient adherence. Therefore, a 2- to 4-week follow-up was advised after each medication addition or titration. In addition to medication management and visit frequency, recommended laboratory and clinical monitoring were specified. The product was a one-page reference which could be displayed in exam rooms, precepting rooms, and other key clinical locations to inform discussions and guide patient care. This document, along with the full protocol, is published in Shaffer et al.20 EHR improvements Modifications to the electronic health record (EHR) system were implemented between June 2022 and October 2023. These updates included lowering the EHR red letter alert from BP of 160+/90+ to 140+/90+, creating a dotphrase to easily display a patient's most recent six BP readings, establishing a repeat BP alert for elevated BP readings, automatic referrals to primary care for patients with a high BP without a primary care provider, creating a Hypertension SmartSet, and launching a Hypertension Express Lane—an EHR package containing items such as relevant patient clinical metrics, evidence-based hypertension guidance, and shortcuts to orders for common diagnostic procedures and referrals. Regular monitoring of hypertension data No quality improvement program can be successful without a method of ongoing monitoring to determine the uptake of interventions and guide ongoing efforts for improvement. Although this healthcare system has a long history of monitoring the final outcome of population rates of BP control at the system- and provider-level, it only included BP control rate data which was usually 2 months old, and reflected the patient's most recent BP regardless of service location. In addition, patient attribution was determined in part by payor assignment rather than location of service. This data remains a useful reflection of overall population control rates, but not of real-time protocol adherence and can fluctuate as office populations change. To ensure transparency and accountability in adhering to best-practice in hypertension management, an internal platform depicting real-time hypertension driver metrics was established in September 2023, and the results were reviewed monthly in departmental and system-wide primary care meetings. This allowed for recognition of common problems and the ability to spot practice outliers which helped focus education and interventions strategically. Protocol implementation and managing behavioral change The role of the whole team in improving blood pressure control was an emphasis in the HEARTS program and in our local implementation. Specifically, nursing staff were empowered and equipped to improve accurate blood pressure measurements with confirmatory measurements, if needed. This was tracked at the site-level and when resistance was met from physicians who felt that the practice was slowing down their patient care, our physician and nursing leadership intervened to educate and trouble-shoot, affirming the important role of nursing in this process and working collaboratively to ensure patient flow continues. Likewise, the use of follow up visits with nursing or pharmacy team members helped returning patients to be cared for more quickly and achieve their target blood pressure. HEARTS maturity index Evaluation of this healthcare system's implementation and adherence to the principles of the HEARTS Initiative was assessed using the HEARTS Maturity Index.29 This index examined 8 different domains focusing on factors that drive population-wide improvements in BP control and reduction of cardiovascular events.29 Two individuals with detailed involvement in our local hypertension program development, implementation, and evaluation independently assessed this healthcare system's status before the quality improvement initiatives began and after implementation to determine the degree of change across the 8 domains. The evaluators then convened and agreed upon final scores. This healthcare system's baseline score was 2 out of a total of 21 possible points, denoting a level 1 rating. The post-intervention score increased to 11 out of 21 possible points, signifying a level 3 rating. Specific pre- and post-intervention domain scores are outlined in Table 2. Table 2Prior and current states of hypertension management assessed using the HEARTS Maturity Index.DriverPrior StateScoreCurrent StateScoreBP Measurement AccuracyNo standard nurse training in automated cuffsNo standard for repeating elevated BPVariable equipment availability0Standard initial and annual competency training in manual and automated BP measurementSpecialty and primary care standard for repeat BP measurement if elevatedExtensive deployment of automated devices with expectation of consistent use2CVD Risk AssessmentASCVD calculator deployed in EHR, use not trackedStatin use only measured in select high risk groups0No substantial change0Standardized Treatment ProtocolNo standard protocol0Standard protocol developed including fixed dose combination medications.2Treatment IntensificationNo standard guideline or practice for pharmaceutical advancement0Treatment intensification of confirmed hypertension with target <140/90 for all and <130 SBP for high-risk groups but not tracked.Rate of normalization of BP at 6 weeks tracked and currently at 61%.0Continuity of care and follow-upNo system-wide standard for follow-up and intervention0System-wide standard of 2–4 weeks follow-up for elevated patients and 3–6 months follow-up when controlled. 6-week follow-up tracked currently at 37%.0Team-Base Care and Task ShiftingBP measured by clinical staff. Rare nurse or pharmacy follow-up visits for BP, no specific protocol.1BP measured by clinical staff.Nurse BP visits guided by protocol with provider supervision.Med titration by pharmacists but not nurses or medical assistants.Rate and proportion of these visits not tracked.1Medication Refill FrequencyNo standard for med refill pattern, often 1 month1Standard 90-day supply for stable patients with 3 refills, EHR default in preference lists3System for performance evaluationFirst BP control rate per site tracked and data given to practice managers by quality specialist team, often with generalized suggestions0Hypertension driver metrics by site reviewed monthly by primary care medical and nursing leadership to assess adherence to guidelines. Deviations identified and focused interventions planned.3Total (Max 21)Pre-Implementation2Post Implementation11 Prior and current states of hypertension management assessed using the HEARTS Maturity Index. Measures and outcomes Data was extracted from electronic health records. Sociodemographic characteristics included age, sex, race/ethnicity, preferred language, and insurance payor and were self-reported by patients. Insurance payor was categorized as commercial (e.g., commercial, Blue Cross, and Managed Care), Medicaid (e.g., Medicaid, Medicaid MCO, and Pending Medicaid), Medicare (e.g., Medicare and Medicare Advantage), self-pay, or other (e.g., Liability, Tricare, Worker's Comp, and other). Clinical factors consisted of whether anti-hypertensive medication was ordered at baseline (i.e. index EBP encounter) and history of comorbidities. Comorbidities, including history of diabetes, coronary artery disease, and chronic kidney disease, were identified using ICD-10 codes. EBP was defined as a BP reading ≥140 mmHg systolic and/or ≥90 mmHg diastolic consistent with Healthcare Effectiveness Data and Information Set (HEDIS) measures during the study period.30 The index EBP encounter was the first encounter at one of the primary care sites in which the patient presented with EBP during the study period. Our study was not limited to patients with confirmed hypertension but aimed to evaluate the HEARTS-derived program among patients with EBP of any cause given that the program's initiatives also prioritized hypertension prevention and promoting best-practice in BP measurement, such as obtaining multiple BP readings. Based on the American Academy of Family Physicians’ recommendations for treating hypertension and prior literature,7,31 the primary outcome was at-target BP, defined as a follow-up BP reading of <140 mmHg systolic and <90 mmHg diastolic. This was prior to the 2025 AHA guidelines suggesting systolic target of 130 mmHg for all patients.32 The follow-up BP was the most recent BP measurement between the index EBP measurement and 6 months from the index EBP measurement, even if the most recent BP occurred during the same visit as the index EBP measurement. Although the index EBP was taken at one of the family or internal medicine centers providing primary care services, the follow-up BP could have been taken at any location within this health system. Statistical analysis Descriptive statistics and bivariate analyses, including Pearson's chi-squared tests and Kruskal–Wallis rank sum tests, were used to evaluate demographic and clinical differences between cohorts by year of index EBP encounter. All patients (i.e. both new and existing to this healthcare system) whose first presentation of EBP during the study period occurred in a 2021 encounter were classified as the pre-intervention cohort. The post-intervention cohort was classified as patients whose first presentation of EBP during the study period occurred during a 2024 encounter. Given the gradual dissemination of the predominate hypertension initiatives throughout the healthcare system between 2022 and 2023, the washout period was defined as patients whose first EBP during the study period occurred between January 1, 2022 and December 31, 2023. Generalized linear mixed-effects models were conducted to investigate the association between study period and reaching at-target BP within 6 months of the index EBP encounter. Primary care site was included as a random intercept. In addition to primary care site-level clustering, multivariable models adjusted for study period, age, sex, race/ethnicity, preferred language, insurance payor, regional market, history of chronic kidney disease, history of coronary artery disease, history of diabetes, anti-hypertensive medication ordered at baseline, baseline systolic blood pressure value, and diastolic blood pressure value. Models were estimated with an adaptive Gauss-Hermite quadrature and a direct Quasi-Newton optimization approach. These models were conducted for all eligible EBP patients as well as for relevant subgroups of EBP patients. In the subgroup analyses, a covariate was not included in the adjusted models if the subgroup was based on the covariate; for instance, age was not included in the subgroup analysis of EBP patients between 18 and 49 years old. Given the low percent of missing data for sex (<0.01%), race/ethnicity (1.37%), and preferred language (0.04%), no correction for missingness was applied. A p-value of <0.05 was utilized as the threshold for significance, and R was used to conduct these analyses. Role of the funding source There was no funding source for this study. Results Sample characteristics Among 191,418 adult patients presenting with EBP during the study period, the demographic composition significantly differed by cohort as the health care system expanded (Table 3). For instance, only one-fourth (25.1%) of the 2021 cohort were between 18 and 49 years old, while 37.6% of the 2024 cohort were between 18 and 49 years old. Comorbidities, including a history of chronic kidney disease, coronary artery disease, or diabetes, as well as anti-hypertensive medication ordered at baseline significantly differed by cohort (all p < 0.001). Mean systolic BP at baseline dropped from 148.3 mmHg (standard deviation [SD] = 13.4 mmHg) in the 2021 cohort to 146.7 mmHg (SD = 13.5 mmHg) in the 2024 cohort while the mean diastolic BP at baseline rose from 86.3 mmHg (SD = 11.5 mmHg) in the 2021 cohort to 88.8 mmHg (SD = 10.7 mmHg) in the 2024 cohort. Table 3Demographics and clinical characteristics of adult patients presenting with elevated blood pressure at eligible primary care clinics, stratified by cohort.aCharacteristicOverall N = 191,418Cohorts by year of index elevated blood pressure encounterp-valueb2021 cohort N = 78,9572022 cohort N = 48,5142023 cohort N = 35,8552024 cohort N = 28,092Demographics Age (years), n (%)<0.001 18–49 years old58,367 (30.5%)19,786 (25.1%)15,294 (31.5%)12,719 (35.5%)10,568 (37.6%) 50–64 years old58,997 (30.8%)24,098 (30.5%)15,168 (31.3%)11,226 (31.3%)8505 (30.3%) 65+ years old74,054 (38.7%)35,073 (44.4%)18,052 (37.2%)11,910 (33.2%)9019 (32.1%) Sex, n (%)<0.001 Female108,407 (56.6%)45,306 (57.4%)27,282 (56.2%)20,166 (56.2%)15,653 (55.7%) Male83,009 (43.4%)33,649 (42.6%)21,232 (43.8%)15,689 (43.8%)12,439 (44.3%) Race/ethnicity, n (%)<0.001 White or Caucasian130,507 (69.1%)53,901 (68.9%)33,572 (70.0%)24,498 (69.5%)18,536 (67.8%) Black or African American47,928 (25.4%)20,657 (26.4%)11,903 (24.8%)8495 (24.1%)6873 (25.1%) Hispanic5037 (2.7%)1723 (2.2%)1190 (2.5%)1131 (3.2%)993 (3.6%) Other5317 (2.8%)1954 (2.5%)1299 (2.7%)1124 (3.2%)940 (3.4%) Preferred language, n (%)<0.001 English188,201 (98.4%)77,963 (98.8%)47,828 (98.6%)35,108 (98.0%)27,302 (97.3%) Spanish1914 (1.0%)594 (0.8%)402 (0.8%)446 (1.2%)472 (1.7%) Other1232 (0.6%)379 (0.5%)270 (0.6%)283 (0.8%)300 (1.1%) Insurance payor, n (%)<0.001 Commercial90,808 (47.4%)32,856 (41.6%)23,487 (48.4%)19,030 (53.1%)15,435 (54.9%) Medicaid11,350 (5.9%)4369 (5.5%)3001 (6.2%)2296 (6.4%)1684 (6.0%) Medicare78,451 (41.0%)37,523 (47.5%)19,163 (39.5%)12,470 (34.8%)9295 (33.1%) Self-pay8180 (4.3%)3239 (4.1%)2183 (4.5%)1547 (4.3%)1211 (4.3%) Other2629 (1.4%)970 (1.2%)680 (1.4%)512 (1.4%)467 (1.7%)Regional market, n (%)<0.001 Market A138,069 (72.1%)57,789 (73.2%)34,839 (71.8%)25,759 (71.8%)19,682 (70.1%) Market B53,349 (27.9%)21,168 (26.8%)13,675 (28.2%)10,096 (28.2%)8410 (29.9%)Comorbidities and clinical factors Chronic kidney disease, n (%)<0.001 No152,096 (79.5%)58,164 (73.7%)39,449 (81.3%)30,195 (84.2%)24,288 (86.5%) Yes39,322 (20.5%)20,793 (26.3%)9065 (18.7%)5660 (15.8%)3804 (13.5%) Coronary artery disease, n (%)<0.001 No159,779 (83.5%)63,029 (79.8%)40,948 (84.4%)31,046 (86.6%)24,756 (88.1%) Yes31,639 (16.5%)15,928 (20.2%)7566 (15.6%)4809 (13.4%)3336 (11.9%) Diabetes, n (%)<0.001 No146,523 (76.5%)57,010 (72.2%)37,750 (77.8%)28,827 (80.4%)22,936 (81.6%) Yes44,895 (23.5%)21,947 (27.8%)10,764 (22.2%)7028 (19.6%)5156 (18.4%) Anti-hypertensive medication ordered at baseline, n (%)<0.001 No158,671 (82.9%)64,316 (81.5%)40,489 (83.5%)30,121 (84.0%)23,745 (84.5%) Yes32,747 (17.1%)14,641 (18.5%)8025 (16.5%)5734 (16.0%)4347 (15.5%)Baseline blood pressure Systolic<0.001 Mean (SD)147.4 (13.4)148.3 (13.4)147.0 (13.4)146.6 (13.5)146.7 (13.5) Median (Q1–Q3)145.0 (140.0–154.0)146.0 (140.0–154.0)145.0 (140.0–153.0)145.0 (140.0–152.0)145.0 (140.0–153.0) Diastolic<0.001 Mean (SD)87.4 (11.2)86.3 (11.5)87.7 (11.0)88.5 (10.7)88.8 (10.7) Median (Q1–Q3)89.0 (80.0–94.0)88.0 (80.0–93.0)90.0 (81.0–94.0)90.0 (82.0–94.0)90.0 (82.0–94.0)Follow-up blood pressure taken within 6 months of index elevated blood pressure At-target (i.e. <140 mmHg systolic and <90 mmHg diastolic), n (%)<0.001 No73,749 (38.5%)30,762 (39.0%)18,773 (38.7%)13,656 (38.1%)10,558 (37.6%) Yes117,669 (61.5%)48,195 (61.0%)29,741 (61.3%)22,199 (61.9%)17,534 (62.4%)Bold text indicates statistical significance, p-value < 0.05.aNumbers may not sum to the total sample size due to missing data.bPearson's Chi-squared test; Kruskal–Wallis rank sum test. Demographics and clinical characteristics of adult patients presenting with elevated blood pressure at eligible primary care clinics, stratified by cohort.a Bold text indicates statistical significance, p-value < 0.05. Numbers may not sum to the total sample size due to missing data. Pearson's Chi-squared test; Kruskal–Wallis rank sum test. Target BP within 6 months of index EBP encounter The percentage of EBP patients reaching at-target BP within 6 months of index EBP significantly differed between cohorts (2021 cohort = 61.0%; 2022 cohort = 61.3%; 2023 cohort = 61.9%; 2024 cohort = 62.4%; p < 0.001). After adjusting for site-level clustering, age, sex, race/ethnicity, preferred language, insurance payor, regional market, chronic kidney disease history, coronary artery disease history, diabetes history, baseline anti-hypertensive medication ordering, baseline systolic BP, and baseline diastolic BP, the odds of reaching at-target BP within 6 months of index EBP encounter were 1.14 times higher in the post-intervention cohort than in the pre-intervention cohort (adjusted odds ratio [aOR] = 1.14; 95% confidence interval [CI] = 1.11–1.18; Table 4). Table 4Descriptive statistics and multivariable mixed-effects analysis of predictors associated with reaching at-target blood pressure within 6 months of index elevated blood pressure encounter among adult patients presenting with elevated blood pressure at one of the eligible primary care clinic sites during the pre-intervention (i.e. 2021) or post-intervention (i.e. 2024) period.aPredictorsFollow-up blood pressure taken within 6 months of index elevated blood pressure did not reach targetb N = 41,320Follow-up blood pressure taken within 6 months of index elevated blood pressure reached target N = 65,729aOR (95% CI)c,dp-valueStudy period, n (%) Pre-intervention30,762 (39.0%)48,195 (61.0%)– Post-intervention10,558 (37.6%)17,534 (62.4%)1.14 (1.11–1.18)<0.001Age (years), n (%) 18–49 years old13,003 (42.8%)17,351 (57.2%)– 50–64 years old12,415 (38.1%)20,188 (61.9%)1.22 (1.18–1.27)<0.001 65+ years old15,902 (36.1%)28,190 (63.9%)1.13 (1.07–1.20)<0.001Sex, n (%) Female22,506 (36.9%)38,453 (63.1%)– Male18,813 (40.8%)27,275 (59.2%)0.84 (0.82–0.86)<0.001Race/ethnicity, n (%) White or Caucasian27,115 (37.4%)45,322 (62.6%)– Black or African American11,263 (40.9%)16,267 (59.1%)0.87 (0.84–0.90)<0.001 Hispanic1048 (38.6%)1668 (61.4%)1.09 (0.98–1.20)0.10 Other1187 (41.0%)1707 (59.0%)0.90 (0.83–0.98)0.013Preferred language, n (%) English40,560 (38.5%)64,705 (61.5%)– Spanish436 (40.9%)630 (59.1%)0.91 (0.78–1.07)0.27 Other304 (44.8%)375 (55.2%)0.85 (0.72–1.01)0.059Insurance payor, n (%) Commercial19,493 (40.4%)28,798 (59.6%)– Medicaid2439 (40.3%)3614 (59.7%)1.03 (0.97–1.09)0.28 Medicare16,691 (35.7%)30,127 (64.3%)1.13 (1.08–1.19)<0.001 Self-pay2156 (48.4%)2294 (51.6%)0.77 (0.72–0.82)<0.001 Other541 (37.6%)896 (62.4%)1.08 (0.96–1.20)0.19Regional market, n (%) Midlands11,450 (38.7%)18,128 (61.3%)– Upstate29,870 (38.6%)47,601 (61.4%)0.91 (0.83–1.00)0.042Chronic kidney disease, n (%) No32,877 (39.9%)49,575 (60.1%)– Yes8443 (34.3%)16,154 (65.7%)1.19 (1.15–1.23)<0.001Coronary artery disease, n (%) No34,748 (39.6%)53,037 (60.4%)– Yes6572 (34.1%)12,692 (65.9%)1.15 (1.11–1.19)<0.001Diabetes, n (%) No32,048 (40.1%)47,898 (59.9%)– Yes9272 (34.2%)17,831 (65.8%)1.27 (1.23–1.31)<0.001Anti-hypertensive medication ordered at baseline, n (%) No33,782 (38.4%)54,279 (61.6%)– Yes7538 (39.7%)11,450 (60.3%)1.00 (0.97–1.04)0.94Baseline systolic blood pressure, Median (Q1–Q3)146.0 (140.0–156.0)145.0 (140.0–153.0)0.99 (0.99–0.99)<0.001Baseline diastolic blood pressure, Median (Q1–Q3)89.0 (80.0–94.0)88.0 (80.0–93.0)1.00 (1.00–1.00)0.082Bold text indicates statistical significance, p-value < 0.05.aNumbers may not sum to the total sample size due to missing data.bValues were presented as n (%) for categorical measures and as median (Q1-Q3) for continuous metrics in the descriptive columns.caOR, Adjusted odds ratio; CI, Confidence interval.dThe multivariable models adjusted for all predictors elucidated in this table and accounted for clustering at the primary care site-level using a random intercept. Descriptive statistics and multivariable mixed-effects analysis of predictors associated with reaching at-target blood pressure within 6 months of index elevated blood pressure encounter among adult patients presenting with elevated blood pressure at one of the eligible primary care clinic sites during the pre-intervention (i.e. 2021) or post-intervention (i.e. 2024) period.a Bold text indicates statistical significance, p-value < 0.05. Numbers may not sum to the total sample size due to missing data. Values were presented as n (%) for categorical measures and as median (Q1-Q3) for continuous metrics in the descriptive columns. aOR, Adjusted odds ratio; CI, Confidence interval. The multivariable models adjusted for all predictors elucidated in this table and accounted for clustering at the primary care site-level using a random intercept. Subgroup analyses In the subgroup analyses, the post-intervention period was generally associated with greater adjusted odds of reaching at-target BP within 6 months of the index EBP encounter when compared to pre-intervention for select patient subgroups (Fig. 1). This pattern was consistent across age groups, sex, regional market, coronary artery disease history, diabetes history, and anti-hypertensive medication ordered at baseline. Specifically, higher adjusted odds of achieving at-target BP within 6 months of the index EBP encounter in the post-intervention cohort, compared to the pre-intervention cohort, were observed among EBP patients between 18 and 49 years old, 50–64 years old, and 65+ years old; among both female and male EBP patients; and among EBP patients who were White/Caucasian or Black/African American. Similar improvements were seen in EBP patients preferring English, EBP patients with commercial insurance or Medicare, across both regional markets, EBP patients without chronic kidney disease history, and among EBP patients with or without coronary artery disease history, diabetes history, or baseline anti-hypertensive medication orders. Adjusted odds of reaching at-target blood pressure within 6 months of index elevated blood pressure encounter for the post-intervention period, compared to pre-intervention period, among all eligible patients and by patient subgroups. In addition to study period, all models were adjusted for primary care site-level clustering, age, sex, race/ethnicity, preferred language, insurance payor, regional market, history of chronic kidney disease, history of coronary artery disease, history of diabetes, anti-hypertensive medication ordered at baseline, and baseline systolic and diastolic blood pressure values. However, if a patient subgroup (e.g. EBP patients in Market A) was based on a covariate (e.g. regional market), this covariate was not included in the adjusted model for that subgroup analysis. Discussion Within this quality improvement study of nearly 200,000 adult patients with EBP in southeastern US, implementation of a multicomponent and team-based, HEARTS-derived program was associated with improved BP control–specifically achievement of at-target BP within 6 months of index EBP encounter–compared to the pre-implementation period. This finding was also consistent in most patient subgroups. Further, as intended by the HEARTS approach,29 this series of initiatives continue to serve as an ongoing and evolving quality improvement program by identifying and implementing additional opportunities to improve BP care. For instance, within this health system, a standardized note template/documentation containing alarm symptoms and guidance on how to escalate EBP readings was created for primary care nursing and pharmacy staff in April 2025 to assist them with BP recheck visits. Although this healthcare system focused on HEARTS-based initiatives to improve BP measurement, standard treatment protocol development, and improvements in task shifting, an overlooked area that the index identified was the incorporation of atherosclerotic cardiovascular disease (ASCVD) assessment in the hypertension protocol. While it was mentioned as influencing treatment goals, ASCVD assessment was not included as a discrete step, nor dyslipidemia treatment as an intervention. Doing so could further emphasize the focus on ACSVD risk reduction rather than obtaining a specific numerical BP target. The findings of the HEARTS Maturity Index reflected this healthcare system's current priorities regarding further hypertension control, including standardizing the use of nurse or pharmacist-led visits and improving follow-up rates. It also highlights an additional system priority to improve the rate of statin prescribing in high-risk diseases such as diabetes. Improvements in BP-related outcomes need to be considered based on changes in overall patient population. For instance, the present study has revealed problematic reductions in the age of EBP onset. One explanation for this finding could be that the HEARTS-derived program assisted in earlier detection of EBP. Another rationale is that patients are presenting with EBP at earlier ages. This is particularly concerning given that prior literature using 2023 data found that only 82.3% of US adults between 18 and 44 years old self-reported visiting primary care in the past year, compared to 90.5% of adults 45–64 years old and 96.2% of adults 65+ years old.33 Early onset hypertension is also associated with greater risk for suboptimal clinical outcomes, such as midlife cognitive impairment, cardiovascular events, chronic kidney disease, or mortality.34, 35, 36, 37, 38 These works highlight the importance of healthcare systems vigilantly monitoring changes in EBP populations and adopting HEART-based initiatives tailored towards higher risk patients. This work aligns with other quality improvement efforts demonstrating successful integration of initiatives such as HEARTS, the Kaiser Permanente Northern California model, and Target: BP™.8,11,12 Implementation of HEARTS-based programs have been shown to improve BP control in Chile, Cuba, Colombia, Mexico, Venezuela, and Guatemala.8,39,40 The subgroup analyses showed that the intervention made a greater impact in our higher risk patients, such as those with older age or history of diabetes, which is consistent with the guidelines the council promoted in the organization. Our findings also suggested a need for additional evaluation and tailoring of BP initiatives to support select EBP patient subgroups in achieving BP control. Thus, further research on unmeasured structural factors or confounders and tailored initiatives to support all patient populations to achieve BP control is necessary. This quality improvement effort serves as an informative stepping-stone for other healthcare systems in the US to implement HEARTS-based initiatives. Challenges faced and lessons learned Systemwide implementation of any initiative is not without challenges. The authors and other members of the council were surprised to find that the predominate barriers focused on the standardization of accurate BP measurement and remeasurement, as well as timely follow-up of patients with elevated values. Although challenges with obtaining and distributing equipment capable of computing average BPs to all primary care sites were anticipated, a dearth of standard competency by nursing staff in using automated cuffs was unexpected and required early intervention. In terms of any provider resistance to BP rechecks, in some cases, it was due to distrust of automated, compared to manual, BP readings. In others, physicians were concerned about the potential impact on clinical flow from delays in rooming. However, the healthcare system's new tools tracking driver metrics by site allowed identification of outliers quickly. The council addressed barriers on a case-by-case basis using published evidence and customizing workflows as needed. However, not all challenges were unanticipated. Scheduling 2- to 4-week follow-up visits proved difficult as many provider schedules were already booked out months in advance and opening access for an increased volume of BP follow-ups was daunting. One solution was to create a standard nurse visit, including symptom assessment, documentation, and escalation protocols for either nurse or pharmacist-led BP visits. This degree of task shifting to the care team was new and a bit intimidating for some offices, especially those with lean clinical staffing. Conversely, the council anticipated significant physician reservations concerning a standard pharmacologic treatment algorithm. However, early involvement of key stakeholders, a strong evidence-based process, and a variety of educational approaches focused on improving patient outcomes was associated with virtually no resistance to the treatment guideline itself, only appreciation for the effort invested and for clear guidance, especially among early career providers. Strengths and limitations To the authors' knowledge, this quality improvement initiative is the first of its kind to detail the large-scale integration of HEARTS-derived interventions within a healthcare system in the United States. Indeed, the abundant sample size of 191,418 adult patients presenting with EBP and inclusion of 66 primary care sites with full integration of this healthcare system's adaptation of HEARTS provides support regarding the ability to implement these initiatives among diverse primary care settings and patient populations. Moreover, the detailed description of the HEARTS-derived initiatives' integration, challenges, and lessons learned offers other healthcare centers a comprehensive roadmap on implementing the HEARTS Initiative in their system. Further, the integration of EHR-based tools and real-time monitoring platforms provides clinical teams with salient and rapid insights for their patients, thereby improving their ability to coordinate further systemwide efforts to promote cardiovascular care. However, notable limitations are present within this study. First, patient-level factors related to EBP treatment, such as adherence to anti-hypertensive medications and modifications to diet and physical activity, were unable to be assessed. Likewise, the EBP risk factors assessed in this study were not all inclusive; for instance, obesity, genetic predispositions, or the use of highly prevalent substances or medications that may contribute to EBP, such as alcohol or caffeine, were not examined.32 Second, this study did not account for pre-intervention time trends as would be possible through a more complex interrupted time series approach. Third, direct and indirect effects of the COVID-19 pandemic could have contributed to patients' access, ability, or willingness to seek routine wellness and primary care services thus delaying appointments related to initiating or adjusting anti-hypertensive medication regimens or engaging in lifestyle hypertension interventions during the pre-intervention period, especially during the beginning of the pandemic.41,42 Fourth, new and existing patients were included in this study; it is possible that existing patients with worse cardiovascular health were more likely to seek annual primary care services, resulting in the pre-intervention cohort having a greater proportion of patients with more risk factors for EBP. However, National Health Interview Survey (NHIS) data from 2023 revealed that 91.6% of US adults with hypertension visited primary care in the past year.33 Fifth, this study defined EBP as a single BP reading of ≥140 mmHg systolic and/or ≥90 mmHg diastolic, rather than the multiple BP measurements taken over multiple occasions as recommended by American College of Cardiology and American Heart Association's 2025 clinical guidelines for hypertension.32 Thus, awareness is prudent when applying this data to patients with confirmed hypertension. Sixth, as a component of the HEARTS-based program, protocols for measuring BP changed over time to improve accuracy in BP readings; thus, it is possible that our findings may have been impacted by an improvement in BP measurement accuracy. Seventh, barriers and facilitators to integrating HEARTS-based interventions were presented narratively within this paper, rather than through a systematic approach, such as through the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework.43 Future efforts to conduct interviews or focus groups with patients, nursing staff, primary care physicians, and leadership could serve as beneficial guides to the further development and integration of systemwide initiatives to improve primary care. Conclusions and next steps As one of the first studies to evaluate the implementation of HEARTS-based initiatives within a large, integrated healthcare system in the US, our findings revealed greater odds of reaching at-target BP within 6 months of the index EBP encounter for the post-intervention cohort, compared to those in the pre-intervention group. Indeed, these findings persisted in most patient subgroups, suggesting that this series of interventions could be successfully implemented and promote BP control within a US-based sample. Although this study intervened on health-system barriers impacting BP care, future projects assessing patients’ engagement with lifestyle modifications, access and adherence to anti-hypertensive medication regimens, in addition to health literacy of and attitudes towards EBP could result in clinically meaningful improvements in BP control and cardiovascular health on a population level. Contributors Authors’ contributions are listed as follows: MS: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Resources, Data curation, Writing (original draft, review, & editing), Visualization, Supervision, and Project administration. ER: Writing (original draft, review & editing). KW: Investigation, and Writing (original draft, review, & editing). RSS: Conceptualization, Methodology, Software, Investigation, Writing (original draft, review, & editing), and Visualization. JBG: Conceptualization, Validation, Resources, and Writing (original draft, review, & editing). GT: Methodology, Formal analysis, and Writing (review & editing). KG: Conceptualization, Resources, Writing (original draft, review, & editing). DJD: Conceptualization, Methodology, Writing (review & editing). CCH: Methodology, Data curation, Formal analysis, Writing (original draft, review & editing). Data sharing statement This article's data will not be available for sharing. The hypertension protocol is separately published.20 Data access, responsibility, and analysis MS and CCH had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Declaration of interests RSS reported being a physician advisor to Pfizer outside of the submitted work. No other disclosures were reported by the authors. Acknowledgements The authors would like to acknowledge Amanda Benites from the InVio health network for all of her work promoting the implementation of these interventions, Dr. John Emerson for initial guidance in structuring this analysis, Todd Hanson for data curation, and our clinical leadership for their support in large-scale quality improvement efforts. DJD and ER are Consultant Advisors for the Pan American Health Organization. This quality improvement study did not have any external funding. Footnotes Supplementary data related to this article can be found at https://doi.org/10.1016/j.lana.2026.101518. Contributor Information Mark Shaffer, Email: Mark.Shaffer@prismahealth.org. Emily Ridley, Email: Emily.Ridley@prismahealth.org. Kerri Williams, Email: Kerri.Williams@prismahealth.org. Rebecca S. Smith, Email: Rebecca.Smith@prismahealth.org. James B. Gettys, Email: Jim.Gettys@prismahealth.org. Gregg M. Talente, Email: Gregg.Talente@prismahealth.org. Katherine Gettys, Email: Katherine.Gettys@prismahealth.org. Donald J. DiPette, Email: Donald.DiPette@prismahealth.org. Carolin C. Hoeflich, Email: Carolin.Hoeflich@prismahealth.org. Supplementary data Supplemental Content References Associated Data Supplementary Materials Supplemental Content